Polydex Pharmaceuticals (OTCPK:POLX.F) - Stock Price, News & Analysis

POLX.F Stock Overview

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. More details

POLX.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 74.3% per year over past 5 years

Does not have a meaningful market cap ($7M)

Does not have meaningful revenue ($5M)

Polydex Pharmaceuticals Limited Competitors

Endexx

OTCPK:EDXC

US$5.3m

Aytu BioPharma

NasdaqCM:AYTU

US$10.0m

Mystic Holdings

OTCPK:MSTH

US$6.5m

Sonoma Pharmaceuticals

NasdaqCM:SNOA

US$3.8m

Price History & Performance

Summary of all time highs, changes and price drops for Polydex Pharmaceuticals
Historical stock prices
Current Share Price	US$1.99
52 Week High	US$2.01
52 Week Low	US$0.55
Beta	0.45
11 Month Change	-1.19%
3 Month Change	6.20%
1 Year Change	175.83%
33 Year Change	130.93%
5 Year Change	89.14%
Change since IPO	-90.37%

Recent updates

Shareholder Returns

	POLX.F	US Pharmaceuticals	US Market
7D	0.3%	2.8%	2.2%
1Y	175.8%	11.8%	32.6%

Return vs Industry: POLX.F exceeded the US Pharmaceuticals industry which returned -4.4% over the past year.

Return vs Market: POLX.F exceeded the US Market which returned 15.2% over the past year.

Price Volatility

Is POLX.F's price volatile compared to industry and market?
POLX.F volatility
POLX.F Average Weekly Movement	6.1%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: POLX.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine POLX.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1979	20	George Usher	www.polydex.com

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry.

Polydex Pharmaceuticals Limited Fundamentals Summary

How do Polydex Pharmaceuticals's earnings and revenue compare to its market cap?
POLX.F fundamental statistics
Market cap	US$6.82m
Earnings (TTM)	-US$842.27k
Revenue (TTM)	US$4.74m

1.4x

P/S Ratio

-8.1x

P/E Ratio

Is POLX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
POLX.F income statement (TTM)
Revenue	US$4.74m
Cost of Revenue	US$4.60m
Gross Profit	US$142.86k
Other Expenses	US$985.13k
Earnings	-US$842.27k

Last Reported Earnings

Apr 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.25
Gross Margin	3.01%
Net Profit Margin	-17.76%
Debt/Equity Ratio	2.8%

How did POLX.F perform over the long term?

See historical performance and comparison

Polydex Pharmaceuticals OTCPK:POLX.F Stock Report